Traceable Nanoparticles with Dual Targeting and ROS Response for RNAi-Based Immunochemotherapy of Intracranial Glioblastoma Treatment | |
Qiao, Chenmeng1,2,3; Yang, Jun1; Shen, Qi1; Liu, Ruiyuan1; Li, Yanhui1; Shi, Yuanjie1; Chen, Jingli1; Shen, Yanqin3; Xiao, Zuobing4,5; Weng, Jie2 | |
刊名 | ADVANCED MATERIALS |
2018-05-03 | |
卷号 | 30期号:18 |
关键词 | Immunochemotherapy Intracranial Brain Tumors Magnetic Resonance Imaging (Mri) Temozolomide (Tmz) Tumor Growth Factor-beta (Tgf-beta) |
ISSN号 | 0935-9648 |
DOI | 10.1002/adma.201705054 |
文献子类 | Article |
英文摘要 | The chemotherapy of glioblastoma is severely hindered by the immunosuppressive tumor microenvironment, especially the tumor growth factor beta (TGF-beta), an immunosuppressive cytokine. In this study, it is proposed to employ RNAi-based immunomodulation to modify the tumor immune microenvironment and improve the effect of chemotherapy. Herein, a nanotheranostic system (Angiopep LipoPCB(Temozolomide+BAP/siTGF-beta), ALBTA) with dual targeting and ROS response is established for intracranial glioblastoma treatment. The traceable nanoparticles exhibit strong siRNA condensation, high drug loading efficiency, good serum stability, and magnetic property. They can efficiently cross the blood-brain barrier and target to glioblastoma cells via receptor-mediated transcytosis. The zwitterionic lipid (distearoyl phosphoethanol-amine-polycarboxybetaine lipid) in ALBTA promotes endosomal/lysosomal escape, and thus enhances the cytotoxicity of temozolomide and improves gene silencing efficiency of siTGF-beta ALBTA significantly improves the immunosuppressive microenvironment and prolongs the survival time of glioma-bearing mice. Moreover, ALBTA can be accurately traced by MRI in brain tumors. The study indicates that this immunochemotherapeutic platform can serve as a flexible and powerful synergistic system for treatment with brain tumors as well as other brain diseases in central nervous system. |
WOS关键词 | Small Interfering Rna ; Tumor Microenvironment ; Cationic Liposomes ; Malignant Glioma ; Cancer-therapy ; Drug-delivery ; In-vitro ; Mechanisms ; Temozolomide ; Strategy |
WOS研究方向 | Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics |
语种 | 英语 |
WOS记录号 | WOS:000431615100003 |
资助机构 | National High Technology Research and Development Program(2016YFA0200303) ; National Natural Science Foundation of China(51573188 |
内容类型 | 期刊论文 |
源URL | [http://ir.ipe.ac.cn/handle/122111/24434] |
专题 | 过程工程研究所_生化工程国家重点实验室 |
作者单位 | 1.Chinese Acad Sci, State Key Lab Biochem Engn, Inst Proc Engn, Beijing 100190, Peoples R China 2.Southwest Jiaotong Univ, Key Lab Adv Technol Mat MOE, Sch Mat Sci & Engn, Chengdu 610031, Sichuan, Peoples R China 3.Jiangnan Univ, Wuxi Med Coll, Wuxi 214122, Peoples R China 4.Shanghai Inst Technol, Sch Perfume & Aroma Technol, Shanghai 201418, Peoples R China 5.Shanghai Res Inst Fragrance & Flavor Ind, Shanghai 200232, Peoples R China |
推荐引用方式 GB/T 7714 | Qiao, Chenmeng,Yang, Jun,Shen, Qi,et al. Traceable Nanoparticles with Dual Targeting and ROS Response for RNAi-Based Immunochemotherapy of Intracranial Glioblastoma Treatment[J]. ADVANCED MATERIALS,2018,30(18). |
APA | Qiao, Chenmeng.,Yang, Jun.,Shen, Qi.,Liu, Ruiyuan.,Li, Yanhui.,...&Zhang, Xin.(2018).Traceable Nanoparticles with Dual Targeting and ROS Response for RNAi-Based Immunochemotherapy of Intracranial Glioblastoma Treatment.ADVANCED MATERIALS,30(18). |
MLA | Qiao, Chenmeng,et al."Traceable Nanoparticles with Dual Targeting and ROS Response for RNAi-Based Immunochemotherapy of Intracranial Glioblastoma Treatment".ADVANCED MATERIALS 30.18(2018). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论